Menu
Search
|

Menu

Close
X

Catalyst Pharmaceuticals Inc CPRX.OQ (NASDAQ Stock Exchange Capital Market)

3.05 USD
-0.03 (-0.97%)
As of Jul 21
chart
Previous Close 3.08
Open 3.07
Volume 67,923
3m Avg Volume 190,326
Today’s High 3.13
Today’s Low 3.04
52 Week High 4.51
52 Week Low 2.20
Shares Outstanding (mil) 84.55
Market Capitalization (mil) 234.22
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.056
FY17
-0.214
FY16
-0.218
FY15
-0.251
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
6.89
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-42.00
14.61
Return on Equity (TTM)
vs sector
-42.26
16.34

EXECUTIVE LEADERSHIP

Patrick McEnany
Chairman of the Board, President, Chief Executive Officer, Since 2006
Salary: $425,000.00
Bonus: $85,000.00
Alicia Grande
Chief Financial Officer, Vice President, Treasurer, Since 2011
Salary: $240,000.00
Bonus: $48,000.00
Steven Miller
Chief Operating Officer, Chief Scientific Officer, Since 2011
Salary: $300,000.00
Bonus: $100,000.00
David Muth
Executive Vice President, Chief Commercial Officer, Since 2015
Salary: --
Bonus: --
M. Douglas Winship
Vice President - Regulatory Operations, Since 2006
Salary: $198,414.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

355 Alhambra Cir Ste 1250
CORAL GABLES   FL   33134-5038

Phone: +1305.5292522

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

SPONSORED STORIES